1. Home
  2. CRNX vs HLN Comparison

CRNX vs HLN Comparison

Compare CRNX & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$33.73

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo Haleon plc (Each representing two)

HLN

Haleon plc (Each representing two)

HOLD

Current Price

$9.78

Market Cap

43.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNX
HLN
Founded
2008
2022
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Package Goods/Cosmetics
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
43.7B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
CRNX
HLN
Price
$33.73
$9.78
Analyst Decision
Strong Buy
Buy
Analyst Count
9
1
Target Price
$74.78
N/A
AVG Volume (30 Days)
1.0M
7.9M
Earning Date
05-07-2026
02-26-2026
Dividend Yield
N/A
1.86%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,039,000.00
N/A
Revenue This Year
$722.66
$7.04
Revenue Next Year
$183.79
$4.58
P/E Ratio
N/A
$49.05
Revenue Growth
N/A
N/A
52 Week Low
$24.10
$8.71
52 Week High
$57.99
$11.42

Technical Indicators

Market Signals
Indicator
CRNX
HLN
Relative Strength Index (RSI) 29.20 36.39
Support Level $33.23 $9.59
Resistance Level $37.23 $9.96
Average True Range (ATR) 1.62 0.14
MACD 0.13 -0.06
Stochastic Oscillator 8.33 12.66

Price Performance

Historical Comparison
CRNX
HLN

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About HLN Haleon plc (Each representing two)

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

Share on Social Networks: